The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score (RS) in early breast cancer (EBC).
 
Rima Patel
No Relationships to Disclose
 
Malin Hovstadius
No Relationships to Disclose
 
Melanie Wain Kier
No Relationships to Disclose
 
Erin Moshier
No Relationships to Disclose
 
Brittney Shulman Zimmerman
No Relationships to Disclose
 
Krystal Pauline Cascetta
No Relationships to Disclose
 
Shabnam Jaffer
No Relationships to Disclose
 
Joseph A. Sparano
Stock and Other Ownership Interests - Metastat
Consulting or Advisory Role - Adgero Biopharmaceuticals; AstraZeneca; BMSi; Cardinal Health; Celgene; Celldex; CStone Pharmaceuticals; Daiichi Sankyo; Epic Sciences; Genentech/Roche; GlaxoSmithKline; Juno Therapeutics; Lilly; Merrimack; Novartis; Pfizer; Pfizer; Prescient Therapeutics
Speakers' Bureau - Certara Inc; Eisai
Research Funding - Deciphera (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Prescient Therapeutics (Inst); Radius Health (Inst)
Travel, Accommodations, Expenses - Adgero Biopharmaceuticals; AstraZeneca; Menarini Silicon Biosystems; Myriad Genetics; Pfizer; Rhenium Medical; Roche/Genentech
 
Amy Tiersten
Consulting or Advisory Role - AstraZeneca; Eisai; Immunomedics; Novartis; Puma Biotechnology; Roche/Genentech
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Novartis; pfizer